Adlai Nortye (NASDAQ:ANL) CFO Sells $83,880.00 in Stock

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) CFO Xiaofeng Ye sold 6,000 shares of the business’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $13.98, for a total transaction of $83,880.00. Following the sale, the chief financial officer owned 153,424 shares of the company’s stock, valued at approximately $2,144,867.52. This represents a 3.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xiaofeng Ye also recently made the following trade(s):

• On Wednesday, August 26th, Xiaofeng Ye sold 5,667 shares of Adlai Nortye stock. The shares were sold at an average price of $14.25, for a total value of $80,754.75.

Adlai Nortye Trading Up 9.5%

Shares of ANL stock traded up $1.31 on Wednesday, reaching $15.05. The stock had a trading volume of 147,795 shares, compared to its average volume of 397,755. Adlai Nortye Ltd. Sponsored ADR has a 1 year low of $0.88 and a 1 year high of $17.25. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.65 and a current ratio of 9.55. The company has a 50 day simple moving average of $11.91 and a 200 day simple moving average of $11.13.

Institutional Trading of Adlai Nortye

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Affinity Asset Advisors LLC bought a new position in shares of Adlai Nortye in the first quarter worth about $1,140,000. ADAR1 Capital Management LLC bought a new position in shares of Adlai Nortye during the 1st quarter valued at approximately $816,000. Renaissance Technologies LLC purchased a new stake in Adlai Nortye in the 1st quarter worth approximately $457,000. Braidwell LP purchased a new stake in Adlai Nortye in the 2nd quarter worth approximately $9,145,000. Finally, Seven Fleet Capital Management LP bought a new stake in Adlai Nortye during the 2nd quarter worth approximately $1,302,000. Hedge funds and other institutional investors own 35.21% of the company’s stock.

Analyst Upgrades and Downgrades

ANL has been the topic of several research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Wall Street Zen raised shares of Adlai Nortye from a “hold” rating to a “buy” rating in a research report on Saturday. Oppenheimer started coverage on shares of Adlai Nortye in a research note on Thursday, May 28th. They issued an “outperform” rating and a $32.00 price objective on the stock. JonesTrading assumed coverage on shares of Adlai Nortye in a research note on Thursday, May 14th. They issued a “buy” rating and a $22.00 price objective on the stock. Finally, Cantor Fitzgerald began coverage on shares of Adlai Nortye in a report on Monday, June 22nd. They issued an “overweight” rating on the stock. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $24.25.

About Adlai Nortye

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.